ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) has earned an average recommendation of "Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.67.
A number of analysts have recently commented on ABVX shares. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th.
Check Out Our Latest Report on ABVX
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the fourth quarter valued at approximately $29,000. R Squared Ltd bought a new stake in ABIVAX Société Anonyme in the fourth quarter worth $36,000. Bank of America Corp DE boosted its stake in ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares during the period. Ameriprise Financial Inc. bought a new position in ABIVAX Société Anonyme during the fourth quarter valued at $85,000. Finally, Guggenheim Capital LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at $92,000. Institutional investors own 47.91% of the company's stock.
ABIVAX Société Anonyme Stock Performance
Shares of ABVX traded up $0.02 during trading hours on Friday, reaching $5.94. 477,305 shares of the company's stock traded hands, compared to its average volume of 116,713. ABIVAX Société Anonyme has a 12 month low of $5.50 and a 12 month high of $17.02. The firm's 50 day simple moving average is $6.72 and its 200-day simple moving average is $8.75.
About ABIVAX Société Anonyme
(
Get Free ReportABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
